Why Is Echo IQ (ASX:EIQ) Share Price Down Today?

Sonal Goyal

01 September 2026 01:20 PM AEST

Why Is Echo IQ (ASX:EIQ) Share Price Down Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Echo IQ (ASX:EIQ) shares traded at $1.345, down 4.95% on 1 September 2026.
The company continues progressing toward commercialisation of its AI-driven cardiac diagnostic technology.
Its latest quarterly update highlighted progress toward U.S. expansion and regulatory milestones for EchoSolv HF.
Management is targeting a significant Revenue inflection during 2026 as customer adoption continues.

Share Price Snapshot

Echo IQ (ASX:EIQ) shares were trading at $1.345 on 1 September 2026, down 4.95% on the session.

Echo IQ is a healthtech company developing artificial intelligence-driven diagnostic technology focused on cardiac conditions, with its flagship product, EchoSolv HF, designed to assist in the detection and assessment of heart failure using AI analysis of echocardiogram data.

The company's latest quarterly update reinforced a narrative of steady, methodical progress toward broader commercialisation. Management highlighted continued progress toward U.S. expansion, a critical market for any medical diagnostics technology. Alongside this, the update referenced regulatory milestones specifically relevant to EchoSolv HF. Customer adoption was also noted as continuing. The company remains loss-making at this stage, with cash reserves being directed toward development, clinical validation and commercial rollout. Management has set an internal target of achieving a significant revenue inflection during 2026.

Catalysts to Watch

Further regulatory milestones or approvals relevant to EchoSolv HF, particularly any developments supporting U.S. market access, would represent a significant positive catalyst. Evidence of accelerating customer adoption, including new hospital or clinical partnerships, would help validate commercial viability. Clinical validation studies demonstrating accuracy and clinical Utility could also support broader adoption. The targeted revenue inflection during 2026 is the most significant catalyst flagged by management itself.

Key Risks

Echo IQ remains a loss-making, pre-scale commercialisation company, meaning it continues to rely on cash reserves and potentially further Capital raisings, which could dilute existing shareholders. Regulatory Risk is significant for any medical diagnostics technology. Commercial execution risk is also relevant, as translating approval and validation into sustained revenue growth requires successful sales and Marketing capabilities. Competition within AI-driven medical diagnostics is likely to intensify over time.

Conclusion

Echo IQ continues to make measured progress toward commercialising its AI-driven cardiac diagnostic technology, with continued advancement on U.S. expansion, regulatory milestones and customer adoption. Separately, the stock's trading activity on 1 September 2026 showed a modest intraday decline. For investors, EIQ represents a speculative but strategically positioned opportunity within AI-driven healthcare diagnostics.

Q1: What was Echo IQ's share price on 1 September 2026?

Q2: What is EchoSolv HF?

Q3: Is Echo IQ currently profitable?

Q4: What is Echo IQ's revenue target for 2026?

Q5: What are the key risks for Echo IQ investors?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.